{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:31:36Z","timestamp":1790195496956,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Children's Art for Children's Cancer"},{"name":"24 Hours of Booty BMT Research Endowment"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD34+ cell selection minimizes graft\u2010versus\u2010host disease (GVHD) after haploidentical donor stem cell transplant but is associated with slow immune recovery and infections. We report a Phase I\/II study of prophylactic donor lymphocyte infusion (DLI) followed by methotrexate (MTX) GVHD prophylaxis after CD34\u2010selected haploidentical donor transplant. A prophylactic DLI was given between day +30 and +42. Rituximab was given with DLI for the last 10 patients. The goal of the study was to determine a DLI dose that would result in a CD4+ cell count\u2009&gt;\u2009100\/\u00b5L at Day +120 in\u2009\u2265\u200966% of patients with\u2009\u2264\u200933% grade II\u2010III,\u2009\u2264\u200917% grade III, and no grade IV acute GVHD by Day +180. Thirty\u2010five patients with malignant (<jats:italic>n<\/jats:italic>\u2009=\u200925) or nonmalignant disease (<jats:italic>n<\/jats:italic>\u2009=\u200910) were treated after CD34\u2010selected haploidentical donor peripheral blood stem cell transplant. The DLI dose of 5 \u00d7 10<jats:sup>4<\/jats:sup>\/kg met the CD4\/GVHD goal with 67% of patients having CD4+ cells\u2009&gt;\u2009100\/\u00b5L and 11% grade II\u2010IV acute GVHD. The cumulative incidence of chronic GVHD was 16%. Fatal viral and fungal infections occurred in 11%. The 2 year estimated overall survival was 69% and the relapse rate was 14% for patients in remission at transplant. There was no effect of NK alloreactivity on relapse. Nine of ten patients at the target DLI dose cohort of 5 \u00d7 10<jats:sup>4<\/jats:sup>\/kg are alive with median follow\u2010up of 18 mos (range 6\u201029). Delayed prophylactic DLI and MTX was associated with promising outcomes at the target DLI dose. This trial was registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>, # NCT01027702.<\/jats:p>","DOI":"10.1002\/ajh.24949","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T07:02:54Z","timestamp":1508396574000},"page":"169-178","source":"Crossref","is-referenced-by-count":12,"title":["Donor lymphocyte infusion and methotrexate for immune recovery after T\u2010cell depleted haploidentical transplantation"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-9340","authenticated-orcid":false,"given":"Andrew L.","family":"Gilman","sequence":"first","affiliation":[{"name":"Pediatric Blood and Marrow Transplantation, Levine Children's Hospital at Carolinas Medical Center Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Leung","sequence":"additional","affiliation":[{"name":"Pediatric Blood and Marrow Transplantation, St. Jude Children's Research Hospital Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"Pediatric Allergy, Immunology, Blood and Marrow Transplant Division, Benioff Children's Hospital, University of California \u2013 San Francisco San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cannon","sequence":"additional","affiliation":[{"name":"Clinical Trials, Levine Cancer Institute Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Epstein","sequence":"additional","affiliation":[{"name":"Transplant Center, Carolinas Medical Center Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Barnhart","sequence":"additional","affiliation":[{"name":"Transplant Center, Carolinas Medical Center Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Shah","sequence":"additional","affiliation":[{"name":"Clinical Trials, Levine Cancer Institute Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hyland","sequence":"additional","affiliation":[{"name":"Clinical Trials, Levine Cancer Institute Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Fukes","sequence":"additional","affiliation":[{"name":"Clinical Trials, Levine Cancer Institute Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Biostatistics, University of North Carolina \u2013 Chapel Hill  North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052638"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405584"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639831"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198509263131301"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810223391702"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.117"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702996"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704303"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12400"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.027"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198202183060703"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.07.005"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.644"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283051"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.324"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705885"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004"},{"issue":"5","key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood-2002-01-0294","article-title":"Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non\u2010malignant diseases: influence of CD34 cell dose and HLA disparity on treatment\u2010related mortality and survival","volume":"100","author":"Wagner JE","year":"2002","journal-title":"Blood."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2470"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6886"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan EM","year":"1958","journal-title":"J Am Statistical Assoc."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb04697.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/323335"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.003"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2010.03.008"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564997"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.186"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.101"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.87"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3830"},{"issue":"10","key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V91.10.3654","article-title":"Semiquantitative Epstein\u2010Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV\u2010induced lymphoproliferative disease after stem cell transplantation","volume":"91","author":"Lucas KG","year":"1998","journal-title":"Blood."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703779"},{"issue":"11","key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood.V85.11.3302.bloodjournal85113302","article-title":"Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft\u2010host tolerance allows for persistent antileukemic reactivity without severe graft\u2010versus\u2010host disease","volume":"85","author":"Johnson BD","year":"1995","journal-title":"Blood."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703803"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/152581603322023043"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-565069"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563817"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.11.016"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:14:42Z","timestamp":1694715282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/ajh.24949"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24949","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]}}}